dc.contributor.author |
Аxmedov X.S. , Xalmetova F.I. |
|
dc.date.accessioned |
2024-12-17T06:01:37Z |
|
dc.date.available |
2024-12-17T06:01:37Z |
|
dc.date.issued |
2024 |
|
dc.identifier.citation |
Toshkent |
en_US |
dc.identifier.uri |
http://repo.tma.uz/xmlui/handle/1/377 |
|
dc.description.abstract |
It is known that RA is an autoimmune disease characterized by chronic inflammation of connective tissue, lead- ing to joint damage and functional impairment. Immune system dysregulation, particularly involving cytokines like TNF-α and IL-6, plays a crucial role in RA development. Current treatment strategies focus on early diagnosis, aggres- sive anti-inflammatory therapy, and the use of innovative gene-engineered biological drugs (GEBD) in combination with traditional medications like methotrexate. The goal is to achieve clinical remission, reduce joint damage, and im- prove patients’ quality of life. While GEBDs have shown efficacy in RA treatment, their early use may not always be necessary or cost-effective. Comorbid conditions and the impact of the COVID-19 pandemic on autoimmune diseases, including RA, are also areas of ongoing research. Additionally, the role of vitamin D deficiency in RA pathogenesis and joint remodeling post-pandemic is being explored. |
en_US |
dc.language.iso |
en |
en_US |
dc.relation.ispartofseries |
UDK;616.34-002.36-003.728-06:616.76-002.77:618.065:579 |
|
dc.subject |
rheumatoid arthritis, GEBD, joints syndrome |
en_US |
dc.title |
Modern treatment methods of rheumatoid arthritis |
en_US |
dc.type |
Article |
en_US |